Jim Cramer's Stop Trading: Jazz Pharmaceuticals Faces Music

NEW YORK (TheStreet) -- Jazz Pharmaceuticals (JAZZ) "did not hit the numbers, so the stock is down," TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Cramer's Stop Trading" segment. 

The company missed analysts' estimates for its top- and bottom-line results. Cramer said he's highlighting Jazz Pharmaceuticals because of how poorly biotechnology stocks have performed over the past two months.

Turning to WhiteWave Foods (WWAV), "I thought that quarter was amazing," he said of the company's top and bottom line earnings beat. 

He added that Hain Celestial Group (HAIN) is also doing very well, and its CEO Irwin Simon is "too clever" for the short-sellers.

- - Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Medivation Founder Takes Helm at Axovant, Shares Spike

Trevena, Synergy Lead Biotech Movers

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix